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Several countries have adopted the IAEA’s method to establish their 
own national auditing networks. Further development is being 
considered to check not only the reference condition, i.e.beam 
calibration, but also non-reference conditions, such as irregularly 
shaped and wedged beams, rotational, helical or not intensity 
modulated RT beams(Table), proton therapy beams. 
 
Reference Region Average SD (%) 
Gillis et al., 2005 
ESTRO-QUASIMODO 
Europe 1.014 
0.997 
1.6 
3.6 
Tomsej et al., 2005 
GORTEC 
Europe 0.992 3.9 
Ibott et al., 2006 
RPC-RTOG 
US 0.99 
0.99 
8 
7 
Tomsej et al., 2007 
ESTRO-OECI 
Europe 0.966 
0.978 
2.4 
1.5 
 
ESTRO booklet 9 Guidelines for the verification of IMRT, Table 7.3: 
Results from studies of the accuracy of dose determinations of IMRT 
treatments. 
Recent advances in radiotherapy focus on the need for a systematic 
quality assurance program that balances patient safety and quality 
with available resources. External audit programmes for radiotherapy 
QA are also effective. Both postal dosimetry audit and clinical trial 
radiotherapy QA, especially for advanced technologies, in 
collaboration with global networks, will serve to enhance patient 
safety and quality of care. 
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Purpose/Objective: The accuracy of photon dose calculation in the 
out-of-field regions is often neglected despite its importance for 
organs at risk and peripheral dose evaluation. The present work 
assessed the dose calculation accuracy of the Anisotropic Analytical 
Algorithm (AAA) and the Acuros XB algorithms implemented in the 
Eclipse treatment planning system, in the regions shielded by the jaw, 
or the MLC, or both MLC and jaw for flattened (6 and 10 MV) and 
unflattened (6 and 10 FFF MV) beams. The largest difference to out-
of-field dose coming from the two beams (flattened and unflattened) 
is due to the head scatter, where for FFF beams a lower contribution 
is expected due to the lack of flattening filter scattering. 
Materials and Methods: Six and 10 MV, flattened and unflattened 
beams, were from a TrueBeam (Varian Medical Systems, Palo Alto, 
USA), equipped with Millennium 120-MLC. Depth doses in water, out of 
the field, parallel to the field edge were acquired at 1, 2, 3, 5 and 10 
cm distance from the field edge. Lateral field side was set as 1, 5 and 
10 cm. The following shielding modalities were used to set the beam: 
(1) jaw defined field (MLC retracted); (2) MLC defined field (jaws set 
to 40x35 cm2); (3) jaw+MLC defined field (both positioned at the field 
edge). Measurements were acquired with a 0.125 cm3 ion chamber. All 
measurements were then compared with the corresponding AAA and 
Acuros XB calculations (version11.0.21) in water. 
Four volumetric modulated arc therapy plans (in the RapidArc form) 
were optimized in a water equivalent phantom, PTW Octavius, in a 
way to have a region always shielded by the MLC or jaw+MLC during 
the delivery. A structure was delineated mimicking the target with 
the anterior part of a ring shape of 6 cm external diameter and 3 and 
4 cm thickness (two optimizations); the organ to spare was a 
cylindrical volume at distance of 0.5 cm from the target and with a 
radius of 2 and 1 cm, respectively. Doses to seven points located in 
the shielded region and in the target like structure were measured 
with a 0.125 cm3 ion chamber. Results were compared with the AAA 
and Acuros XB calculations in terms of absorbed dose in a volume as 
the ion chamber sensitive volume.  
Results: In general a good agreement between calculation and 
measurements was found for both algorithms. From depth dose 
analysis the 10 FFF beam resulted, as expected, to offer the lowest 
out-of-field dose. The overall average difference (all energies and 
shielding methods) between measurements and calculations were 
below 0.6% for AAA and below 0.8% for Acuros XB. 
From RapidArc plans analysis the average differences between 
calculation and measurement in the shielded region were -0.9%±0.4% 
and -3.1%±1.3% for AAA and Acuros XB, respectively, relative to the 
mean target dose value. Differences in the target structure were of -
0.5%±2.3%, -0.7%±2.3% for AAA and Acuros XB, respectively. 
Conclusions: The high accuracy required to properly evaluate the out-
of-field dose can be achieved with the analysed algorithms, AAA and 
Acuros XB that showed an accuracy degree in those low dose regions 
similar, relatively to in-field dose, to what obtained for open beams.  
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Purpose/Objective: Assessment of acceptable target dose conformity 
in plans with multiple prescription levels is a challenge due to the 
inevitable over/underdosage at the borderline between dose levels. 
Here, we propose a tool for the evaluation of target dose in treatment 
plans with multiple dose levels, providing a possible contribution to 
level 3 reporting in ICRU report 83. We illustrate the potential of the 
tool in identifying a single plan as suboptimal and identifying a 
systematic change in planning priorities in our institution between 
2010 and 2012. 
Materials and Methods: Dose painted treatment plans with five dose 
levels (DP plans) were evaluated for 20 head and neck cancer 
patients. As a complement to structure specific dose parameters, plan 
specific parameters describing the target dose were used for the 
quality assessment tool. The quality value Q was the basis for the 
evaluation and was used to obtain quality volume histograms (QVH): 
  
A one-dimensional measure, the quality factor, QF, has previously 
been used1 to evaluate target dose: 
 where n is the number of voxels and Qp is the qualityvalue in voxel p. 
We propose to supplement this measure with a 2D QVH tool that is 
based on the experience from previous similar treatment plans. For 
each Q value, the median relative volume, V, and interquartile range 
(iqr) among the group of historical plans was found. An area on the 
QVH corresponding to median(V) ±1.45*iqr was outlined, which in case 
of normal distribution includes 95% of the plans. When evaluating the 
QVH of a new plan, this tool can be used to identify poorer than usual 
dose conformity. We overlaid the QVH plots of 13 clinical 
hypopharyngeal plans from 2010 with 13 hypopharyngeal plans from 
2012, and used the QVH tool to identify a change in plans over time. 
Results: Figure 1 illustrates that one of 20 H&N DP plans was 
identified as suboptimal by the QVH tool, even though it met all 
planning constraints. The plan had more overdosage than what should 
be expected, and was reoptimized and improved (Figure 1, thick dark 
line). The plan QF decreased from 0.056 to 0.045, corresponding well 
to the group average: mean QF 0.047 (range 0.039-0.056). 
Comparison of the 2010 and 2012 plans with the QVH tool clearly 
demonstrated that current treatment plans have less underdosage at 
the expense of more overdosage when compared to the 2010 plans. 
This change is not associated with a change in QF. 
